NASDAQ
No price data available for this timeframe.
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year....
AYAL Capital Advisors Ltd lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 10.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The...
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials....
Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists ...
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board...
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival....
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year....
Advantage Alpha Capital Partners LP cut its position in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 22.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned...
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales....